Concepedia

Virgyl Camberlein

VC

4

Publications

76

Citations

4

H-Index

2020

Active since

Affiliations

Inserm(Current)

Médicaments et Molécules pour Agir sur les Systèmes Vivants

Institut Pasteur de Lille

European Genomic Institute for Diabetes

Université de Lille

Virgyl Camberlein is an author at Inserm specializing in medicine, biochemistry, and molecular docking.

ORCID

Top concepts

Publications per year

2020–2022

4

Publications

4

Multi-component reaction for the preparation of 1,5-disubstituted 1,2,3-triazoles by in-situ generation of azides and nickel-catalyzed azide-alkyne cycloaddition

Virgyl Camberlein, Nicolas Kraupner, Nour Bou Karroum et al. · Tetrahedron Letters · 2021 · 23 citations · Full text

, , +6

Discovery of the First Selective Nanomolar Inhibitors of ERAP2 by Kinetic Target‐Guided Synthesis

Virgyl Camberlein, Charlotte Fléau, Pierre Sierocki et al. · Angewandte Chemie International Edition · 2022 · 21 citations · Full text

, , +15

Modulators of hERAP2 discovered by high-throughput screening

Laura Medve, Ronan Gealageas, Bao Vy Lam et al. · European Journal of Medicinal Chemistry · 2020 · 17 citations · Full text

, , +4

Discovery and Characterization of Synthesized and FDA-Approved Inhibitors of Clostridial and Bacillary Collagenases

Alaa Alhayek, Ahmed S. Abdelsamie, Esther Schönauer et al. · Journal of Medicinal Chemistry · 2022 · 15 citations · Full text

Rows per page

1–4 of 4